{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:50:27Z","timestamp":1788825027948,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>18F-Fluorodeoxyglucose (FDG) PET\/CT is emerging as a tool in the diagnosis and evaluation of pulmonary sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A meta-analysis was conducted with PubMed, Science Direct, MEDLINE, Scopus, and CENTRAL databases searched up to and including September 2023. 1355 studies were screened, with seventeen (<jats:italic>n<\/jats:italic>\u2009=\u2009708 patients) suitable based on their assessment of the diagnostic performance or prognostic value of FDG-PET\/CT. Study quality was assessed using the QUADAS-2 tool. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance. Pooled changes in SUVmax were correlated with changes in pulmonary function tests (PFT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>FDG-PET\/CT in diagnosing suspected pulmonary sarcoidosis (six studies, <jats:italic>n<\/jats:italic>\u2009=\u2009400) had a pooled sensitivity of 0.971 (95%CI 0.909\u20131.000, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001) and specificity of 0.873 (95%CI 0.845\u20130.920)(one study, <jats:italic>n<\/jats:italic>\u2009=\u2009169). Eleven studies for prognostic analysis (<jats:italic>n<\/jats:italic>\u2009=\u2009308) indicated a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653\u20133.453, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001) post-treatment. PFTs displayed improvement post-treatment with a percentage increase in predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257\u201312.436, <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and 3.464% (95%CI -0.205\u20137.132, <jats:italic>p<\/jats:italic>\u2009=\u20090.064), respectively. Reduction in SUVmax correlated significantly with FVC (<jats:italic>r<\/jats:italic>\u2009=\u20090.644, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and DLCO (r\u2009=\u20090.582, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In cases of suspected pulmonary sarcoidosis, FDG-PET\/CT demonstrated good diagnostic performance and correlated with functional health scores. FDG-PET\/CT may help to guide immunosuppression in cases of complex sarcoidosis or where treatment rationalisation is needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical relevance statement<\/jats:title>\n            <jats:p>FDG-PET\/CT has demonstrated a high diagnostic performance in the evaluation of suspected pulmonary sarcoidosis with radiologically assessed disease activity correlating strongly with clinically derived pulmonary function tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>\n                    <jats:italic>In diagnosing pulmonary sarcoidosis, FDG-PET\/CT had a sensitivity and specificity of 0.971 and 0.873, respectively.<\/jats:italic>\n                  <\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>\n                    <jats:italic>Disease activity, as determined by SUVmax, reduced following treatment in all the included studies.<\/jats:italic>\n                  <\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>\n                    <jats:italic>Reduction in SUVmax correlated with an improvement in functional vital capacity, Diffusion Capacity of the Lungs for Carbon Monoxide, and subjective health scoring systems.<\/jats:italic>\n                  <\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00330-024-10949-4","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T18:05:05Z","timestamp":1721757905000},"page":"2222-2232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Meta-analysis of [18F]FDG-PET\/CT in pulmonary sarcoidosis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-9897","authenticated-orcid":false,"given":"Ryan","family":"Donnelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro N.","family":"Franciosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmet E.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"10949_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.2022.1570","volume":"327","author":"JA Belperio","year":"2022","unstructured":"Belperio JA, Shaikh F, Abtin FG et al (2022) Diagnosis and treatment of pulmonary sarcoidosis. JAMA 327:856. https:\/\/doi.org\/10.1001\/jama.2022.1570","journal-title":"JAMA"},{"key":"10949_CR2","doi-asserted-by":"publisher","first-page":"1900444","DOI":"10.1183\/13993003.00444-2019","volume":"54","author":"LM Fidler","year":"2019","unstructured":"Fidler LM, Balter M, Fisher JH, To T, Stanbrook MB, Gershon A (2019) Epidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort study. Eur Respir J 54:1900444. https:\/\/doi.org\/10.1183\/13993003.00444-2019","journal-title":"Eur Respir J"},{"key":"10949_CR3","doi-asserted-by":"publisher","first-page":"56S LP","DOI":"10.1183\/09031936.01.18s320056","volume":"18","author":"U Costabel","year":"2001","unstructured":"Costabel U (2001) Sarcoidosis: clinical update. Eur Respir J 18:56S LP\u201368SS LP. https:\/\/doi.org\/10.1183\/09031936.01.18s320056","journal-title":"Eur Respir J"},{"key":"10949_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/00325481.2017.1251818","volume":"129","author":"V Ramachandraiah","year":"2017","unstructured":"Ramachandraiah V, Aronow W, Chandy D (2017) Pulmonary sarcoidosis: an update. Postgrad Med 129:149\u2013158. https:\/\/doi.org\/10.1080\/00325481.2017.1251818","journal-title":"Postgrad Med"},{"key":"10949_CR5","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","volume":"201","author":"ED Crouser","year":"2020","unstructured":"Crouser ED, Maier LA, Wilson KC et al (2020) Diagnosis and detection of sarcoidosis. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med 201:e26\u2013e51. https:\/\/doi.org\/10.1164\/rccm.202002-0251ST","journal-title":"Am J Respir Crit Care Med"},{"key":"10949_CR6","doi-asserted-by":"publisher","first-page":"TC15","DOI":"10.7860\/JCDR\/2017\/24165.9459","volume":"11","author":"PK Dhagat","year":"2017","unstructured":"Dhagat PK, Singh S, Jain M, Singh SN, Sharma RK (2017) Thoracic sarcoidosis: imaging with high resolution computed tomography. J Clin Diagn Res 11:TC15\u2013TC18. https:\/\/doi.org\/10.7860\/JCDR\/2017\/24165.9459","journal-title":"J Clin Diagn Res"},{"key":"10949_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1515\/jomb-2016-0017","volume":"35","author":"S Popevi\u0107","year":"2016","unstructured":"Popevi\u0107 S, \u0160umarac Z, Jovanovi\u0107 D et al (2016) Verifying sarcoidosis activity: chitotriosidase versus ACE in sarcoidosis - a case-control study. J Med Biochem 35:390\u2013400. https:\/\/doi.org\/10.1515\/jomb-2016-0017","journal-title":"J Med Biochem"},{"key":"10949_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2967\/jnumed.117.196287","volume":"58","author":"P Chareonthaitawee","year":"2017","unstructured":"Chareonthaitawee P, Beanlands RS, Chen W et al (2017) Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med 58:1341\u20131353. https:\/\/doi.org\/10.2967\/jnumed.117.196287","journal-title":"J Nucl Med"},{"key":"10949_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"10949_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk\u2010of\u2010bias VISualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments. Res Synth Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"10949_CR11","first-page":"1571","volume":"47","author":"Y Nishiyama","year":"2006","unstructured":"Nishiyama Y, Yamamoto Y, Fukunaga K et al (2006) Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47:1571\u20131576. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17015889","journal-title":"J Nucl Med"},{"key":"10949_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00259-009-1376-6","volume":"37","author":"RG Keijsers","year":"2010","unstructured":"Keijsers RG, Grutters JC, van Velzen-Blad H, van den Bosch JM, Oyen WJ, Verzijlbergen FJ (2010) 18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 37:1181\u20131188. https:\/\/doi.org\/10.1007\/s00259-009-1376-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10949_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00259-009-1097-x","volume":"36","author":"RG Keijsers","year":"2009","unstructured":"Keijsers RG, Verzijlbergen FJ, Oyen WJ et al (2009) 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 36:1131\u20131137. https:\/\/doi.org\/10.1007\/s00259-009-1097-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10949_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00259-008-0770-9","volume":"35","author":"JJ Braun","year":"2008","unstructured":"Braun JJ, Kessler R, Constantinesco A, Imperiale A (2008) 18F-FDG PET\/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 35:1537\u20131543. https:\/\/doi.org\/10.1007\/s00259-008-0770-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10949_CR15","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1378\/chest.14-1827","volume":"146","author":"VN Maturu","year":"2014","unstructured":"Maturu VN, Agarwal R, Aggarwal AN et al (2014) Dual-time point whole-body 18 F-fluorodeoxyglucose PET\/CT imaging in undiagnosed mediastinal lymphadenopathy. Chest 146:e216\u2013e220. https:\/\/doi.org\/10.1378\/chest.14-1827","journal-title":"Chest"},{"key":"10949_CR16","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2967\/jnumed.121.263598","volume":"63","author":"P Lovinfosse","year":"2022","unstructured":"Lovinfosse P, Ferreira M, Withofs N et al (2022) Distinction of lymphoma from sarcoidosis on 18 F-FDG PET\/CT: evaluation of radiomics-feature\u2013guided machine learning versus human reader performance. J Nucl Med 63:1933\u20131940. https:\/\/doi.org\/10.2967\/jnumed.121.263598","journal-title":"J Nucl Med"},{"key":"10949_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00508-014-0647-9","volume":"127","author":"A Yakar","year":"2015","unstructured":"Yakar A, Yakar F, Sezer M et al (2015) Use of PET-CT for the assessment of treatment results in patients with sarcoidosis. Wien Klin Wochenschr 127:274\u2013282. https:\/\/doi.org\/10.1007\/s00508-014-0647-9","journal-title":"Wien Klin Wochenschr"},{"key":"10949_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","volume":"46","author":"ADM Vorselaars","year":"2015","unstructured":"Vorselaars ADM, Crommelin HA, Deneer VHM et al (2015) Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 46:175\u2013185. https:\/\/doi.org\/10.1183\/09031936.00227014","journal-title":"Eur Respir J"},{"key":"10949_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0505-x","volume":"9","author":"MC Schimmelpennink","year":"2019","unstructured":"Schimmelpennink MC, Vorselaars ADM, Veltkamp M, Keijsers RGM (2019) Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET\/CT: SUVmax versus total lung glycolysis. EJNMMI Res 9:54. https:\/\/doi.org\/10.1186\/s13550-019-0505-x","journal-title":"EJNMMI Res"},{"key":"10949_CR20","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","volume":"138","author":"MC Schimmelpennink","year":"2018","unstructured":"Schimmelpennink MC, Vorselaars ADM, van Beek FT et al (2018) Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis. Respir Med 138:S7\u2013S13. https:\/\/doi.org\/10.1016\/j.rmed.2018.02.009","journal-title":"Respir Med"},{"key":"10949_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","volume":"107","author":"RLM Mostard","year":"2013","unstructured":"Mostard RLM, Verschakelen JA, Van Kroonenburgh MJPG et al (2013) Severity of pulmonary involvement and 18F-FDG PET activity in sarcoidosis. Respir Med 107:439\u2013447. https:\/\/doi.org\/10.1016\/j.rmed.2012.11.011","journal-title":"Respir Med"},{"key":"10949_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/RLU.0b013e31828731f5","volume":"38","author":"DP Sobic-Saranovic","year":"2013","unstructured":"Sobic-Saranovic DP, Grozdic IT, Videnovic-Ivanov J et al (2013) Responsiveness of FDG PET\/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med 38:516\u2013521. https:\/\/doi.org\/10.1097\/RLU.0b013e31828731f5","journal-title":"Clin Nucl Med"},{"key":"10949_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","volume":"6","author":"N Milman","year":"2012","unstructured":"Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B (2012) Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 6:238\u2013247. https:\/\/doi.org\/10.1111\/j.1752-699X.2011.00276.x","journal-title":"Clin Respir J"},{"key":"10949_CR24","first-page":"372","volume":"33","author":"VN Maturu","year":"2016","unstructured":"Maturu VN, Rayamajhi SJ, Agarwal R, Aggarwal AN, Gupta D, Mittal BR (2016) Role of serial F-18 FDG PET\/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis 33:372\u2013380","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10949_CR25","first-page":"123","volume":"28","author":"RG Keijsers","year":"2011","unstructured":"Keijsers RG, Verzijlbergen EJ, van den Bosch JM et al (2011) 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis 28:123\u2013129. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22117503","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10949_CR26","first-page":"143","volume":"25","author":"RGM Keijsers","year":"2008","unstructured":"Keijsers RGM, Verzijlbergen JF, Van Diepen DM, van den Bosch JMM, Grutters JC (2008) 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with Infliximab. Sarcoidosis Vasc Diffus Lung Dis 25:143\u2013150","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10949_CR27","doi-asserted-by":"publisher","first-page":"1823710","DOI":"10.1155\/2018\/1823710","volume":"2018","author":"H Chen","year":"2018","unstructured":"Chen H, Jin R, Wang Y, Li L, Li K, He Y (2018) The utility of 18F-FDG PET\/CT for monitoring response and predicting prognosis after glucocorticoids therapy for sarcoidosis. Biomed Res Int 2018:1823710. https:\/\/doi.org\/10.1155\/2018\/1823710","journal-title":"Biomed Res Int"},{"key":"10949_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1440-1843.2011.01966.x","volume":"16","author":"Y Umeda","year":"2011","unstructured":"Umeda Y, Demura Y, Morikawa M et al (2011) Prognostic value of dual\u2010time\u2010point 18F\u2010fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 16:713\u2013720. https:\/\/doi.org\/10.1111\/j.1440-1843.2011.01966.x","journal-title":"Respirology"},{"key":"10949_CR29","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2967\/jnumed.121.263598","volume":"63","author":"P Lovinfosse","year":"2022","unstructured":"Lovinfosse P, Ferreira M, Withofs N et al (2022) Distinction of lymphoma from sarcoidosis on 18F-FDG PET\/CT: evaluation of radiomics-feature guided machine learning versus human reader performance. J Nucl Med 63:1933\u20131940. https:\/\/doi.org\/10.2967\/jnumed.121.263598","journal-title":"J Nucl Med"},{"key":"10949_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/MCP.0000000000000892","volume":"28","author":"RJ Vender","year":"2022","unstructured":"Vender RJ, Aldahham H, Gupta R (2022) The role of PET in the management of sarcoidosis. Curr Opin Pulm Med 28:485\u2013491. https:\/\/doi.org\/10.1097\/MCP.0000000000000892","journal-title":"Curr Opin Pulm Med"},{"key":"10949_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195:310\u2013320. https:\/\/doi.org\/10.2214\/AJR.10.4923","journal-title":"AJR Am J Roentgenol"},{"key":"10949_CR32","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.jcmg.2020.11.016","volume":"14","author":"M Subramanian","year":"2021","unstructured":"Subramanian M, Swapna N, Ali AZ et al (2021) Pre-treatment myocardial 18FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 14:2008\u20132016. https:\/\/doi.org\/10.1016\/j.jcmg.2020.11.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10949_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CPM.0000000000000136","volume":"23","author":"P Korsten","year":"2016","unstructured":"Korsten P, Strohmayer K, Baughman RP, Sweiss NJ (2016) Refractory pulmonary sarcoidosis. Clin Pulm Med 23:67\u201375. https:\/\/doi.org\/10.1097\/CPM.0000000000000136","journal-title":"Clin Pulm Med"},{"key":"10949_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1513\/AnnalsATS.202208-731ED","volume":"20","author":"ON Obi","year":"2023","unstructured":"Obi ON (2023) Pulmonary sarcoidosis: beyond restriction and forced vital capacity Ann Am Thorac Soc 20:24\u201326. https:\/\/doi.org\/10.1513\/AnnalsATS.202208-731ED","journal-title":"Ann Am Thorac Soc"},{"key":"10949_CR35","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","volume":"22","author":"CA Bonham","year":"2016","unstructured":"Bonham CA, Strek ME, Patterson KC (2016) From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med 22:484\u2013491. https:\/\/doi.org\/10.1097\/MCP.0000000000000301","journal-title":"Curr Opin Pulm Med"},{"key":"10949_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31:496\u2013505. https:\/\/doi.org\/10.1053\/j.sult.2010.10.001","journal-title":"Semin Ultrasound CT MR"},{"key":"10949_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnmt.119.233353","volume":"48","author":"I Sarikaya","year":"2020","unstructured":"Sarikaya I, Albatineh AN, Sarikaya A (2020) Revisiting Weight-Normalized SUV and Lean-Body-Mass\u2013Normalized SUV in PET Studies. J Nucl Med Technol 48:163\u2013167. https:\/\/doi.org\/10.2967\/jnmt.119.233353","journal-title":"J Nucl Med Technol"},{"key":"10949_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-023-01067-6","volume":"23","author":"P Zhang","year":"2023","unstructured":"Zhang P, Chen W, Zhao K et al (2023) Tumor to liver maximum standardized uptake value ratio of FDG-PET\/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer. BMC Med Imaging 23:107. https:\/\/doi.org\/10.1186\/s12880-023-01067-6","journal-title":"BMC Med Imaging"},{"key":"10949_CR39","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/jcm9030890","volume":"9","author":"RGM Keijsers","year":"2020","unstructured":"Keijsers RGM, Grutters JC (2020) In Which Patients with Sarcoidosis Is FDG PET\/CT Indicated? J Clin Med 9:890. https:\/\/doi.org\/10.3390\/jcm9030890","journal-title":"J Clin Med"},{"key":"10949_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13139-014-0289-x","volume":"48","author":"J Park","year":"2014","unstructured":"Park J, Chang KJ, Seo YS et al (2014) Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET\/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Nucl Med Mol Imaging 48:295\u2013302. https:\/\/doi.org\/10.1007\/s13139-014-0289-x","journal-title":"Nucl Med Mol Imaging"},{"key":"10949_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0007-0971(76)90030-9","volume":"70","author":"DJ Hendrick","year":"1976","unstructured":"Hendrick DJ, Blackwood RA, Black JM (1976) Chest pain in the presentation of sarcoidosis. Br J Dis Chest 70:206\u2013210. https:\/\/doi.org\/10.1016\/0007-0971(76)90030-9","journal-title":"Br J Dis Chest"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10949-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:27:53Z","timestamp":1742203673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10949-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["10949"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10949-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The specific guarantor of this publication is Dr David J Murphy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required because this study was a meta-analysis of published works.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}